This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Fascin homolog 1, actin-bundling protein (FSCN1)	<i>In vitro</i> , mouse and human studies suggest that inhibiting FSCN1 could help prevent tumor metastasis. <i>In vitro</i> , the migrastatin analog macroketone bound FSCN1 to prevent actin bundling, thereby inhibiting tumor cell motility. In a mouse model of metastatic breast cancer, inhibition of FSCN1 with macroketone or small interfering RNA reduced lung metastases compared with controls. FSCN1 was upregulated in human breast tumors and associated with lower overall and metastasis-free survival. Ongoing work includes pharmacokinetic and toxicity studies of FSCN1 inhibitors in animals. SciBX 3(16); doi:10.1038/scibx.2010.489 Published online April 22, 2010	Patented; available for licensing	Chen, L. <i>et al. Nature</i> ; published online April 15, 2010; doi:10.1038/nature08978 Contact: Xin-Yun Huang, Cornell University Weill Medical College, New York, N.Y. e-mail: xyhuang@med.cornell.edu